MDRNA said this week that it has signed a new early collaborative effort with an undisclosed company focused on microRNA-directed oncology therapies.
According to the company, the arrangement will focus on the use of MDRNA's DiLA2 delivery technology with proprietary miRNAs in "experimental oncology models." Additional terms of the deal were not disclosed.
The DiLA2 technology relates to synthetic di-alklylated amino acid compounds used to make liposomal delivery formulations.